IL3RA and acute myeloid leukemia: The second new phase II clinical trial is aiming to treat patients with relapsed/refractory CD123+ AML or with Blastic Plasmacytoid Dendritic Cell Neoplasm Immunophenotype-like (BPDCN-IPh-like) AML with Tagraxofusp (ClinicalTrials.gov Identifier: NCT04342962).